BioNTech Stock Tumbles on Cancer Vaccine Trial Halt

BioNTech's (BNTX) stock plummeted 8% on Friday after the company announced it was halting a mid-stage trial of its personalized mRNA cancer vaccine in colorectal cancer. The decision, made by an independent safety board, deemed that continuing the trial would not demonstrate efficacy and recommended termination.

The trial, which paired autogene cevumeran with a wait-and-see approach, aimed to see if the individualized mRNA shot could prevent cancer from coming back longer than waiting. However, despite initial optimism after Moderna and Merck's melanoma win last week, BioNTech's shares are now on track for their worst day since early March.

Wall Street analysts have mixed views on the news, with Morgan Stanley calling it a negative for BioNTech, removing some pipeline optionality. BMO Capital analyst Evan Seigerman termed it 'a clear setback', reducing confidence in the therapy and adjuvant monotherapy approach.